885223-58-5

Basic information

• Product Name: 3-METHYL-1H-INDAZOLE-5-CARBOXYLIC ACID
• Synonyms: 3-METHYL-1H-INDAZOLE-5-CARBOXYLIC ACID;3-METHYL-INDAZOLE-5-CARBOXYLIC ACID;3-methyl-2H-indazole-5-carboxylic acid
• CAS NO: 885223-58-5
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17202
• Mol File: 885223-58-5.mol

Chemical Properties

• Boiling Point: 439.112°C at 760 mmHg
• Flash Point: 219.368°C
• Appearance: /
• Density: 1.422g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.709
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-METHYL-1H-INDAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYL-1H-INDAZOLE-5-CARBOXYLIC ACID(885223-58-5)
• EPA Substance Registry System: 3-METHYL-1H-INDAZOLE-5-CARBOXYLIC ACID(885223-58-5)

Safety Data

• Hazardous Substances Data: 885223-58-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-METHYL-1H-INDAZOLE-5-CARBOXYLIC ACID is used as a building block for the synthesis of various pharmaceutical agents and research chemicals. Its carboxylic acid group allows for versatile chemical bonding with other molecules, facilitating the development of new drugs and compounds with potential therapeutic applications.
Used in Drug Development:
3-METHYL-1H-INDAZOLE-5-CARBOXYLIC ACID is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the creation of novel drug candidates with improved efficacy and safety profiles. Its unique structural features, including the methyl group at the 3-position, can influence the biological activity and pharmacokinetics of the resulting compounds, making it a valuable component in drug discovery and optimization processes.

InChI:InChI=1/C9H8N2O2/c1-5-7-4-6(9(12)13)2-3-8(7)11-10-5/h2-4H,1H3,(H,10,11)(H,12,13)

Upstream product

• 552331-16-5 5-bromo-3-methyl-1H-indazole 
• 124-38-9 carbon dioxide 
• 201286-97-7 methyl 3-methyl-1-[(trifluoromethyl)sulfonyl]-1H-indazole-6-carboxylate 
• 1015068-76-4 3-methyl-1H-indazole-5-carboxylic acid methyl ester 
• 552331-15-4 1-(5-bromo-2-fluorophenyl)ethan-1-ol 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 1086391-06-1 methyl 3-bromo-1H-indazole-5-carboxylate 
• 61700-61-6 1H-indazole-5-carboxylic acid 
• 473416-12-5 methyl 1H-indazole-5-carboxylate 

Downstream Products

• 1404449-32-6 ethyl 3-(1-acetyl-3-methyl-1H-indazol-5-yl)-3-oxopropanoate 
• 1404449-31-5 5-(1-acetyl-3-methyl-1H-indazole-5-carbonyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 885223-59-6 5-(3-methyl-1H-indazol-5-yl)-[1,3,4]thiadiazol-2-ylamine 

Relevant articles and documents

N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARy), inhibit cdJk5-mediated phosphorylation of PP ARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

Maximizing lipophilic efficiency: The use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase

This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS

The invention relates to a compound of a general formula (I): wherein A represents a linking group; Ar1 represents a group formed from an aromatic ring; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a cyclo-C3-C6 alkyloxy group, a C2-C7 alkanoyl group, a halo-C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a halo-C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; a C1-C6 alkyl group optionally having substituent(s); an aryl or heterocyclic group optionally having substituent(s); or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom, a sulfur atom or an imino group. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics

A series of 2-aminothiadiazole of inhibitors of AKT1 is described. SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2). Moderate selectivity observed in several compounds for AKT1 versus PKA is rationalized by X-ray crystallographic analysis. Key compounds showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1. Compound 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40.

PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

HETEROCYCLIC MODULATORS OF PKB

The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein Formula (I). The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

THIADIAZOLE COMPOUNDS AND METHODS OF USE

The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated